Repetitive Transcranial Magnetic Stimulation in SCA3 Patients (NCT05502432) | Clinical Trial Compass
CompletedNot Applicable
Repetitive Transcranial Magnetic Stimulation in SCA3 Patients
China39 participantsStarted 2018-12-17
Plain-language summary
Machado-Joseph Disease (MJD) or spinocerebellar ataxia type 3 (SCA3) is the most common spinocerebellar ataxia worldwide.Repetitive transcranial magnetic stimulation (rTMS) is a form of brain stimulation therapy used to treat depression and cerebellar ataxias. In this randomized, double-blind, sham-controlled study, the investigators will evaluate whether a 15 day treatment with 1 Hz of repetitive transcranial magnetic stimulation (rTMS) can improve symptoms (motor symptoms and non-motor symptoms) in patients with MJD.
Who can participate
Age range20 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
1 .Patients with detectable clinical signs and confirmed genetic diagnosis with SCA3.
2\. SCA3 patients aged 20 - 80 years 3. Patients or their family members have informed consent to the study and signed relevant documents
Exclusion Criteria:
* 1\. Patients who have concomitant epilepsy. 2. History of seizure or heat convulsion. 3. Patients on neuroleptics. 4. History or current unstable hypertension. 5. History of head injury or neurosurgical interventions. 6. History of any metal in the head (outside the mouth). 7. Known history of any metallic particles in the eye, implanted cardiac pacemaker, implanted neurostimulators, surgical clips (above the shoulder line) or any medical pumps.
8\. History of frequent or severe headaches. 9. History of migraine. 10. History of hearing loss. 11. History of cochlear implants 12. History of drug abuse or alcoholism. 13. Pregnancy or not using a reliable method of birth control. 14. Participation in current clinical study.
What they're measuring
1
ICARS
Timeframe: At baseline, during intervention period at 7 days and 15 days immediate after treatment.